Panel of Bloodstream MicroRNAs Predicts Damage from Radiation Exposure
|
By LabMedica International staff writers Posted on 25 May 2015 |
A panel of microRNAs (miRNAs) that can be measured in blood samples is able to predict the extent of long-term radiation injury and likelihood of survival following exposure to high doses of radiation.
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Accidental radiation exposure is a threat to human health that necessitates effective clinical planning and diagnosis. Minimally invasive biomarkers that can predict long-term radiation injury are urgently needed for optimal management after exposure to high levels of radiation.
Investigators at Dana-Farber Cancer Institute (Boston, MA, USA) have identified serum miRNA signatures that indicate long-term impact of total body irradiation (TBI) in mice when measured within 24 hours of exposure.
MiRNAs comprise a family of small noncoding 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer. MiRNAs are made in cells, but some may be detected in the bloodstream.
The investigators systematically assessed the impact of TBI on the bone marrow's blood-cell production system to determine a correlation of residual hematopoietic stem cells (HSCs) with increasing doses of radiation. In addition, they found that 68 of 170 miRNAs detected in blood serum changed with radiation exposure. This number was reduced to a panel that acted as a "signature" of radiation dose.
The investigators reported that mice exposed to sub-lethal (6.5 Gy) and lethal (8.0 Gy) doses of radiation were physically indistinguishable for three to four weeks after exposure. In contrast, a serum miRNA signature was detectable 24 hours after radiation exposure that consistently differentiated these two populations.
By using a radioprotective agent before exposure or radiation mitigation after lethal radiation, the investigators determined that the serum miRNA signature correlated with the impact of radiation on animal health rather than the radiation dose. Finally, using humanized mice that had been engrafted with human CD34+ HSCs, they determined that the serum miRNA signature indicated radiation-induced injury to the human bone marrow cells.
"After a radiation release, there is currently no way to tell who was exposed and who was not, and if someone was exposed, is it lethal or not?" said senior author Dr. Dipanjan Chowdhury, a principal investigator in radiation oncology at Dana-Farber Cancer Institute. "Drugs that can limit bone marrow damage are available but, to be effective, must be given before the appearance of radiation symptoms."
The paper was published in the May 13, 2015, online edition of the journal Science Translational Medicine.
Related Links:
Dana-Farber Cancer Institute
Latest Pathology News
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
- Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
- New AI Model Maps Where Glioblastoma Could Return After Surgery
Channels
Clinical Chemistry
view channel
Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging
Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more
Cystatin C Testing Helps Distinguish Abemaciclib Effect from Kidney Injury
Kidney function monitoring in breast cancer care often relies on serum creatinine, a routine blood marker used to estimate renal function. However, creatinine increases in patients receiving abemaciclib... Read more
Blood-Based Score May Support Targeted Interventions for Healthier Aging
Chronic diseases frequently accumulate with age, complicating efforts to maintain functional independence in older adults. Studies cited by the investigators indicate that about 60% of people over age... Read more
Noninvasive Tests Offer Alternatives to Biopsy for Assessing Advanced Liver Scarring
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects up to one in three adults worldwide and as many as seven in 10 people with obesity or type 2 diabetes. Its more severe form, metabolic... Read moreMolecular Diagnostics
view channel
Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer
Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more
Blood Test Identifies Early Breast and Prostate Cancer Signals Years Before Diagnosis
Breast and prostate cancers are among the most common cancers, yet many are detected only after tumors have become established. Identifying disease earlier could support closer monitoring and help distinguish... Read moreHematology
view channel
Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification
Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more
New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL
Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read moreImmunology
view channel
Roche Gains FDA Clearance for Flexible Respiratory Pathogen Panel
Respiratory infections often cause overlapping viral and bacterial symptoms, making diagnosis more difficult during peak respiratory seasons. This uncertainty can be especially important for high-risk... Read more
Prototype Point-of-Care Lateral Flow Test Aims to Improve Neonatal Sepsis Triage
Sepsis in newborns and young infants remains a major clinical challenge, particularly in low- and middle-income countries. An estimated 2.3 million newborns die each year, with sepsis contributing substantially... Read moreMicrobiology
view channel
Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more
Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more
Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
Preterm birth remains a major obstetric concern and is associated with serious complications in early childhood. Common sexually transmitted infections during pregnancy often cause no symptoms, making... Read more
Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read moreTechnology
view channel
Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
PCR amplifies DNA to enable highly accurate testing, but its reliance on complex, expensive laboratory analyzers has traditionally kept many workflows in centralized settings. A new personal DNA analyzer... Read more
Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
Acute lymphoblastic leukemia (ALL) is a rapidly developing blood cancer that can disrupt production of mature infection-fighting white blood cells within months. More than 120,000 people in the U.... Read moreIndustry
view channel
Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk
Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more







